Traditional chimeric antigen receptor (CAR) T-cell manufacturing requires extended ex vivo cell culture that reduces stem cell memory T cells and antitumor activity. In this study, Dickinson and colleagues assessed the preclinical development and the initial clinical evaluation of YTB323, an autologous CD19-directed CAR T-cell therapy that is manufactured using a next-generation process in less than 2 days. Use of YTB323 in preclinical mouse models demonstrated enhanced in vivo expansion and antitumor activity at lower doses than traditionally manufactured CAR T cells, while, in adults with relapsed/refractory diffuse large B-cell lymphoma, YTB323 showed promising safety and clinical activity at a 25-fold lower dose than tisagenlecleucel.

See article, p. 1982.

The clinical benefit generated by FGFR inhibition in patients with FGFR-driven urothelial cancer is mitigated by the onset of resistance. Facchinetti and colleagues performed sequencing analyses on postprogression tissue biopsies and circulating tumor DNA from 21 patients with FGFR...

You do not currently have access to this content.